Latest news with #personalizedMedicine
Medscape
08-07-2025
- Health
- Medscape
A DNA Test for Every Newborn: Smart or Premature?
During these sweltering early summer days, I've come across several news stories about the use of genetic testing — each deserving a very different level of scrutiny. Three examples come from the United Kingdom, where Health Secretary Wes Streeting is grappling with an NHS in worse shape than healthcare systems in other European countries. In response, he appears committed to investing in genetics as a cornerstone of future predictive and preventive medicine. It's a bold strategy, though not without merit. For example, offering all patients with lung or breast cancer a liquid biopsy— capable of detecting fragments of circulating tumour DNA in the blood — could have clear clinical advantages. This approach would enable physicians to recommend, as early as possible, a personalized therapy tailored to the tumour's molecular profile, with the potential to extend both survival and quality of life. If the UK government does implement such a plan, the benefits could be significant. In fact, there's a strong likelihood that the NHS would recoup the investment over time. A Case Study: The Yellow Card Biobank Equally notable is the new initiative by the Medicines and Healthcare products Regulatory Agency (MHRA): the Yellow Card Biobank, launched to investigate adverse drug reactions. The first focus area is the risk for acute pancreatitis in patients taking semaglutide or other GLP-1 receptor agonists for obesity or type 2 diabetes. To explore whether genetic factors may contribute to this serious complication, doctors have been asked to report relevant cases involving their patients. Those patients will then be invited to provide a saliva or sputum sample for DNA testing. The project aims not only to better understand the molecular mechanisms underlying adverse reactions such as pancreatitis but also to prevent future recurrences in genetically predisposed individuals. This pharmacogenomics effort isn't limited to these medications. It will gradually expand to help reduce adverse events from other drugs as well. In the UK, it's estimated that at least 1 in 6 hospital admissions is due to iatrogenic harm, costing the NHS (in England) roughly £2.2 billion annually for hospital stays alone. According to Alison Cave, chief safety officer at the MHRA, up to one third of all adverse drug reactions could potentially be predicted with genetic testing. Genome Testing for All Newborns Too Much More controversial is the proposal to sequence the entire genome of every newborn in England over the next decade. The goal is to detect not only gene mutations linked to conditions treatable through early diagnosis — similar to existing newborn screening programs — but also many others where knowing the genetic information has no impact on the clinical outcome. This type of sequencing will inevitably identify carrier states and, more problematically, genetic markers associated only with increased statistical risk for such conditions as Alzheimer's disease, Parkinson's disease, and other currently untreatable illnesses. This raises serious ethical questions. How will sufficient numbers of genetic counsellors be trained and funded to support parents in understanding these results? And once these children come of age, could they challenge the government for conducting genomic testing without their consent? The plan aims to build a research database of 500,000 genomes — an undoubtedly valuable resource. But the methods used to collect these data, and the decision to prioritize this initiative over other pressing NHS challenges, are open to debate. Crucially, this approach risks reinforcing a false equivalence between prediction and prevention. While the two can sometimes align to deliver significant public health benefits, they are not universally interchangeable.
Yahoo
26-06-2025
- Business
- Yahoo
Ant Group Launches AI Healthcare App AQ Amid Push into Healthcare Sector
Digital leader aims to capture rising cross-generational demand for public and private healthcare services amid demographic shift and urbanization trends. The launch of AQ enhances Ant Group's comprehensive suite of AI solutions for healthcare, enabling medical institutions and doctors to offer more efficient, accessible, and personalized services. HANGZHOU, China, June 26, 2025--(BUSINESS WIRE)--Ant Group today launched its AI healthcare app, AQ, to accelerate the company's entry into the healthcare sector. The app helps users manage their daily healthcare needs with over 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized medical advice. It also connects users to digital services from over 5,000 hospitals and nearly 1 million doctors across China. By around 2035, over 400 million people, or more than 30% of China's population, will be aged 60 or older, according to projections from China's National Health Commission. This demographic shift is expected to significantly increase healthcare demand in the country. "Ant Group hopes that through AQ, it can provide everyone with a trusted healthcare manager, advancing inclusive healthcare and bringing every Chinese citizen one step closer to a healthier life," said Cyril Han, CEO of Ant Group. The AQ app is powered by Ant Group's Healthcare Large Model, which draws on over a decade of expertise in the healthcare sector. Since 2014, when Ant Group launched its first online hospital appointment-making service on the flagship Alipay digital platform, the company has been supporting the digital and intelligent transformation of China's healthcare industry. The Healthcare Large Model, equipped with advanced medical reasoning and multimodal interaction capabilities, has consistently ranked in first place in the HealthBench and MedBench evaluations. Furthermore, it leverages Ant Group's leading privacy and security technologies to ensure a safe and reliable experience. Through this model, Ant Group is empowering medical institutions and doctors to offer more efficient, accessible, and personalized services to users with AI-enabled solutions. Empowering Medical Institutions with Secure and Efficient AI Integration Healthcare Large Model IntegrationIn March 2025, Ant Group collaborated with IT industry leaders to integrate its advanced healthcare large model into various types of All-in-One Large Model Machine for Healthcare. This solution allows hospitals to deploy AI models on-premises, ensuring efficient and secure use of AI to optimize daily operations and improve patient services. AI Assistant for Hospital ServicesAnt Group is also helping hospitals develop user-facing applications. Angel, an AI agent developed in collaboration with public medical institutions in China's Zhejiang Province, has served over 1,000 medical facilities, handling more than 50 million user interactions. AI Medical Insurance AssistantAdditionally, Ant Group has supported local basic medical insurance institutions across China in developing Yibaoer, an AI agent designed to assist users with medical insurance-related inquiries. AI-Assisted Diagnosis and Patient Education: Extending Doctor Capabilities Beyond Time and Place Constraints AI Doctor AssistantIn January 2025, Ant Group completed the acquisition of Haodf, a leading healthcare platform specializing in online doctor consultations. Together, the two sides launched the AI Doctor Assistant, which supports doctors with AI-assisted diagnosis, medical record management, and patient education. AI Doctor AgentsAnt Group is also collaborating with nearly 200 prominent doctors in China to develop AI Doctor Agents that provide patients with credible, authoritative healthcare advice and medical guidance. This initiative not only empowers individuals to maintain better health but also supports those with limited access to medical resources, ensuring timely, expert care when it's needed most. Through these ongoing initiatives, Ant Group is contributing to the more efficient use of limited medical resources, with the aim of supporting greater medical inclusion. About Alipay As the world becomes increasingly digital, Alipay has evolved from a trusted e-wallet into an all-in-one digital platform for daily services, connecting more than one billion consumers to over 80 million merchants across China. Alipay offers users a secure, seamless mobile payment experience and integrates over 10,000 services across sectors like travel, healthcare, tourism, and entertainment. With digital tools like Alipay Tap!, mini-programs, lifestyle accounts, Alipay enables merchants, institutions, and independent software vendors (ISVs) to enhance operational efficiency and effectiveness. In addition, Alipay is developing a new AI-driven open platform by integrating AI agents to deliver smarter, more personalized services to its users as well as facilitating the digital transformation of the service sector. About Ant Group Ant Group is a global digital technology provider and the operator of Alipay, a leading internet services platform in China, connecting over one billion users to more than 10,000 types of consumer services from partners. Through innovative products and solutions powered by AI, blockchain and other technologies, Ant Group supports partners across industries to thrive through digital transformation in an ecosystem for inclusive and sustainable development. For more information, visit View source version on Contacts Media Inquiries Yinan Duanglobalcomms@
Yahoo
17-06-2025
- Health
- Yahoo
AI-Powered CDSS Enhances Patient Safety with Real-World Data
SAN FRANCISCO, June 17, 2025 /PRNewswire/ -- The growing demand for personalized medicine has accelerated the adoption of Real-World Data (RWD) in healthcare. The Tungs' Taichung MetroHarbor Hospital in Taiwan, in collaboration with AESOP Technology, conducted research on an AI-driven Clinical Decision Support System (CDSS) that leverages RWD to enable safer and more effective clinical decision-making, significantly reducing the risk of potentially inappropriate medications. The findings were published in the Journal of Medical Internet Research recently. RWD encompasses various data types, including electronic health records (EHR), insurance claims, wearable devices, environmental factors, and social determinants of health. It offers a comprehensive view of patient conditions and treatment outcomes. However, effectively utilizing RWD remains a significant challenge. As a key component of RWD, the EHR system is often constrained by the poor design of traditional CDSS. These systems frequently fire irrelevant or low-priority alerts and fail to provide specific recommendations for complex scenarios, such as off-label drug use, multimorbidity, and polypharmacy. This results in alert fatigue among physicians, causing critical alerts and reminders to be overlooked. Consequently, the completeness and accuracy of medical records are compromised, increasing the risk of inappropriate diagnoses or treatments and potentially threatening patient safety. This study addresses these challenges with an integrated AI-powered CDSS that combines MedGuard (now called RxPrime) for prescription appropriateness and DxPrime for diagnostic recommendations. By analyzing 438,558 prescriptions during a year-long trial, the system delivered 10,006 actionable recommendations, achieving a nearly 60% acceptance rate by physicians. Compared to traditional systems, this AI-enhanced approach demonstrated superior precision and practical applicability in real-world clinical settings. The results also revealed high acceptance rates in specialties such as ophthalmology (96.59%) and obstetrics/gynecology (90.01%), indicating strong applicability. In contrast, lower acceptance rates in neurology (38.54%) and hematology-oncology (10.94%) underscore the need for specialty-specific customization to address diverse clinical demands. This research highlights the transformative potential of RWD-driven AI systems with actionable recommendations to improve patient safety and support complex treatment decisions. These advancements foster greater trust and adoption of CDSS by physicians. Furthermore, by enhancing the completeness and accuracy of medical records, these systems elevate the quality of RWD, fostering a positive feedback loop that drives future medical advancements and consistently provides a reliable foundation for data-driven healthcare. About AESOP Technology AESOP Technology harnesses the power of AI to revolutionize clinical decision-making through its Clinical Diagnostic Reasoning Network model. By enhancing the accuracy of diagnoses, medication prescriptions, and medical coding, AESOP aims to improve patient safety and streamline healthcare processes. Its innovative solutions seamlessly integrate with EHR systems to boost efficiency and minimize errors, setting a new standard in medical care. View original content: SOURCE AESOP Technology Sign in to access your portfolio
Yahoo
10-06-2025
- Business
- Yahoo
Rheumatoid Arthritis Global Market Research Report 2025-2035: TNF Inhibitors, IL-6 Inhibitors, and JAK Inhibitors at the Forefront of Developing Biologic Therapies
Explore the evolving Rheumatoid Arthritis (RA) market, driven by advancements in biologics and biosimilars. Highlighting the rising demand for personalized medicine and early intervention, the market faces challenges like high costs and accessibility. Key players include AbbVie, Pfizer, and Amgen. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Rheumatoid Arthritis Market - A Global and Regional Analysis: Focus on Drug Type, Country, and Region - Analysis and Forecast, 2025-2035" report has been added to offering. The global rheumatoid arthritis market is highly competitive, with several major pharmaceutical companies leading the way in the development of innovative treatments. These companies compete in a landscape driven by the demand for more effective and safer therapies to manage this chronic autoimmune condition. Some of the major players include AbbVie, Inc., Pfizer, Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Amgen, Inc., and Regeneron Pharmaceuticals, Inc., among others. These companies are at the forefront of developing biologic therapies such as TNF inhibitors, IL-6 inhibitors, and JAK inhibitors, which have revolutionized the management of rheumatoid the market continues to evolve, competition is not only based on the effectiveness of the therapies but also pricing strategies, especially with the increasing presence of biosimilars, which offer lower-cost alternatives to branded biologics. Furthermore, companies are focusing on expanding their pipeline of next-generation drugs targeting novel pathways to improve patient outcomes and reduce long-term treatment costs. One of the key drivers of the rheumatoid arthritis (RA) market is the advancement in biologic therapies. These biologic agents, including TNF inhibitors (such as Humira and Enbrel), IL-6 inhibitors (such as Actemra), and JAK inhibitors (such as Xeljanz and Olumiant), have revolutionized the treatment landscape for Rheumatoid arthritis, offering patients more targeted and effective treatment options compared to traditional disease-modifying antirheumatic drugs (DMARDs). The introduction of these biologics has significantly improved the management of Rheumatoid arthritis, particularly for moderate to severe cases where conventional treatments were often the growth of biosimilars (cheaper alternatives to biologics) is driving competition and making treatments more accessible, which in turn is expanding the market. With the rising prevalence of Rheumatoid arthritis globally, particularly among aging populations, and the increased recognition of the need for early and aggressive treatment to prevent joint damage, the demand for these advanced biologic therapies continues to grow, further fuelling the market's expansion. Additionally, the development of newer therapies targeting novel pathways in immune modulation and inflammation management is expected to continue driving innovation and market growth in the coming the growth of the rheumatoid arthritis (RA) market, several challenges hinder its continued expansion and effectiveness. One of the most significant barriers is the high cost of biologic therapies and JAK inhibitors, which can be prohibitively expensive, limiting access for patients, especially in low-income regions. This financial burden is compounded by limited access to medications in developing countries where healthcare infrastructure is the adverse effects of biologic treatments, such as increased risk of infections and cardiovascular issues, raise safety concerns, discouraging some patients from initiating or continuing therapy. The late diagnosis of Rheumatoid arthritis also presents a challenge, as delayed treatment often leads to more severe joint damage and worsened the over-reliance on biologics leaves patients with fewer alternatives if these treatments fail. Long-term use of treatments like steroids also brings chronic side effects, such as bone loss and immune suppression. Regulatory hurdles and reimbursement issues further complicate the accessibility of advanced therapies, and the growing prevalence of Rheumatoid arthritis due to aging populations adds pressure to already strained healthcare systems. Lastly, the challenge of personalized treatment, where selecting the right therapy for everyone remains complex, continues to hinder optimal patient care. These challenges underscore the need for innovative approaches to improve access, reduce costs, and ensure better treatment race for market dominance is also influenced by regulatory approvals, patient adherence, and market access strategies across different regions. Given the growing prevalence of Rheumatoid arthritis globally, these major players must also address challenges such as high treatment costs and the need for personalized, precision medicine to maintain a competitive edge. Companies Featured AbbVie, Inc. Boehringer Ingelheim International GmbH Novartis AG Regeneron Pharmaceuticals, Inc. Pfizer, Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. UCB S.A. Johnson & Johnson Amgen, Inc. Eli Lilly and Company Key Topics Covered: 1. Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Epidemiology Analysis1.4 Regulatory Framework1.4.1 Legal Requirement and Framework in the U.S.1.4.2 Legal Requirement and Framework in the E.U.1.4.3 Legal Requirement and Framework in Asia-Pacific1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Rheumatoid Arthritis Market, by Drug Type, ($Million), 2023-20352.1 Overview2.2 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)2.3 Analgesics2.4 Disease-Modifying Antirheumatic Drugs (DMARDs)2.5 Biologics2.6 Others3. Global Rheumatoid Arthritis Market, by Region, ($Million), 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Rheumatoid Arthritis Market, by Country3.1.3.1.1 U.S.3.1.3.1.2 Canada3.2 Europe3.3 Asia-Pacific3.4 Rest of the World4. Global Rheumatoid Arthritis Market: Competitive Landscape and Company Profiles4.1 Key Developments and Strategies4.1.1 Mergers and Acquisitions4.1.2 Synergistic Activities4.1.3 Business Expansions and Funding4.1.4 Product Launches and Approvals4.1.5 Other Activities4.2 Company Profiles4.2.1 Overview4.2.2 Top Products / Product Portfolio4.2.3 Top Competitors4.2.4 Target Customers/End-Users4.2.5 Key Personnel4.2.6 Analyst View5. Research MethodologyFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
Proteomics Market Global and Regional Analysis and Forecasts, 2024-2025 & 2034: Increasing Automation for End-to-End Proteomics Workflow, Significant Number of Collaborations Among Market Players
Key growth catalysts include advancements in mass spectrometry and next-generation sequencing, heightened demand for personalized medicine, increased research funding, and strategic collaborations. With applications in drug discovery, diagnostics, and personalized medicine, the market is expanding rapidly across regions, particularly in Asia-Pacific, fueled by significant healthcare and biotech investments. Notable players include Danaher, Thermo Fisher, and Agilent Technologies, all focusing on innovative solutions. Proteomics Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Proteomics Market - A Global and Regional Analysis: Focus on Offerings, Application, End User, and Region - Analysis and Forecast, 2024-2034" report has been added to global proteomics market is projected to reach $109.71 billion by 2034 from $33.92 billion in 2024, growing at a CAGR of 12.46% during the forecast period 2024-2034. Key factors driving this growth include technological advancements in mass spectrometry and next-generation sequencing, which improve the accuracy of proteomics analysis. The rising demand for personalized medicine, particularly for biomarker discovery and disease profiling, is another major driver. Additionally, increased research funding, strategic collaborations, and the need for early disease detection and effective diagnostics further support market expansion. With an aging population and a higher prevalence of chronic diseases, the demand for proteomics in healthcare and research is expected to continue to rise, ensuring the market sustained growth. Proteomics has significantly advanced disease understanding by uncovering molecular mechanisms in conditions like cancer, cardiovascular, and neurological disorders. It plays a vital role in biomarker discovery, enabling early, precise, and non-invasive diagnostics. In personalized medicine, proteomics supports tailored treatment strategies based on individual protein profiles. The field also aids drug development by identifying new targets and facilitating the study of protein-therapeutic interactions. Clinically, proteomics improves disease monitoring, treatment planning, and therapeutic assessments. Additionally, it drives technological innovation in analytical tools such as mass spectrometry and protein arrays, influencing broader scientific market is expanding in regions such as North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, with Asia-Pacific experiencing rapid growth due to increasing investments in healthcare and biotechnology. Together, these elements drive the continued evolution and growth of the proteomics market globally. China dominated the Asia-Pacific proteomics market in 2022, driven by several key factors. The country has made substantial investments in healthcare, biotechnology, and life sciences research, positioning itself as a leader in the region. China robust infrastructure, large population, and government initiatives, such as the ""Made in China 2025 plan, which emphasizes technological innovation, have further accelerated advancements in proteomics addition, China has become a hub for pharmaceutical and biotechnology companies, fostering an environment conducive to research and development in areas such as drug discovery, personalized medicine, and biomarker identification. The growing demand for proteomics in clinical diagnostics, coupled with the country increasing focus on precision medicine, has bolstered market the rapid adoption of advanced proteomics technologies, such as mass spectrometry and next-generation sequencing, has allowed China to expand its research capabilities and enhance its position in the global market. With a strong emphasis on improving healthcare outcomes and expanding its scientific capabilities, China is expected to continue to lead the proteomics market in the Asia-Pacific region for the foreseeable future. Market Segmentation Highlights Based on offering, the proteomics market is led by product, which held a 72.53% share in 2022. Based on application, the proteomics market is led by drug discovery, which held a 53.64% share in 2022. Based on end user, the proteomics market is led by academic and research institutions, which held a 51.50% share in 2022. Key Market Players Danaher Corporation Thermo Fisher Scientific, Inc. Agilent Technologies, Inc. Bio-rad Laboratories Revvity, Inc. Illumina, Inc. DiaSorin S.p.A. Takara Bio Inc. Merck KGaA Key Attributes: Report Attribute Details No. of Pages 176 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $33.92 Billion Forecasted Market Value (USD) by 2034 $109.71 Billion Compound Annual Growth Rate 12.4% Regions Covered Global Key Topics Covered: Executive SummaryScope and Definition1 Market1.1 Market Outlook1.1.1 Comparative Advantages and Disadvantages of Proteomics Over Other Omics1.1.2 Proteomics Techniques by Introduction with Principles and Advantages/Limitations1.2 Key Findings1.3 Proteomics Market Scenario1.3.1 Realistic Scenario1.3.2 Optimistic Scenario1.3.3 Pessimistic Scenario1.4 Industry Outlook1.4.1 Supply Chain Overview1.5 Trends: Current and Future Impact Assessment1.5.1 Increasing Automation for End-to-End Proteomics Workflow1.5.2 Significant Number of Collaborations among Market Players1.5.3 Growing Proteomics Research to Identify Disease Biomarkers1.6 Patent Analysis1.6.1 Patent Filing Trend (by Country, Year)1.7 Regulatory Framework1.7.1 U.S.1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.1.2 Regulatory Requirements for Research Use Only (RUO) Products1.7.1.3 Requirements under the Clinical Laboratory Improvement Amendments (CLIA) for Clinical Proteomics Labs1.7.2 European Union (EU)1.7.2.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.2.1.1 EU Medical Device Regulation1.7.2.1.2 EU In Vitro Diagnostic Regulation1.7.2.2 Regulatory Requirements for Clinical Proteomics Labs in the EU1.7.3 Japan1.7.3.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.3.2 Regulatory Requirements for Clinical Proteomics Labs in Japan1.7.4 China1.7.4.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5 Brazil1.7.5.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices1.7.5.2 Regulatory Requirements for Clinical Proteomics Labs in Brazil1.8 Product Benchmarking1.9 Market Dynamics Overview1.9.1 Market Drivers1.9.1.1 Increasing Prevalence of Chronic Diseases1.9.1.2 Increasing Technological Advancements1.9.1.3 Advancements in Personalized Medicine and Drug Discovery1.9.2 Market Restraints1.9.2.1 Shortage of Skilled Professionals1.9.2.2 Complexity in Analyzing Data of Proteomics Research1.9.3 Market Opportunities1.9.3.1 Progress in Nanoproteomics Platforms to Enhance and Thoroughly Analyze Natural Protein Complexes2 Global Proteomics Market (by Offering), $Million, 2022-20342.1 Product2.1.1 Kits and Reagents2.1.2 Instruments2.1.2.1 Spectroscopy2.1.2.2 Chromatography2.1.2.3 Electrophoresis2.1.2.4 Others2.1.3 Software2.2 Service3 Global Proteomics Market (by Application), $Million, 2022-20343.1 Drug Discovery3.2 Clinical Diagnostics3.2.1 Cancer3.2.2 Infectious Disease3.2.3 Others3.3 Others4 Global Proteomics Market (by End User), $Million, 2022-20344.1 Biopharmaceutical Companies4.2 Academic and Research Institutions4.3 Hospitals and Diagnostic Laboratories4.4 Others5 Global Proteomics Market (by Region), $Million, 2022-20345.1 Regional Summary5.2 North America5.2.1 Regional Overview5.2.2 Driving Factors for Market Growth5.2.3 Factors Challenging the Market5.2.4 North America Proteomics Market, by Application5.2.5 North America Proteomics Market, by Offering5.2.5.1 North America Proteomics Market, by Product5.2.6 U.S.5.2.7 Canada5.3 Europe5.4 Asia-Pacific5.5 Latin America5.6 Middle East and Africa6 Global NGS in Proteomics Market6.1 NGS in Proteomics6.1.1 Purpose of NGS in Proteomics6.1.2 Application of NGS in Proteomics6.1.2.1 Advantages of NGS-based Proteomics6.1.2.2 Challenges in NGS-based Proteomics6.1.2.3 Future Trends of NGS in Proteomics6.1.3 NGS in Large-Scale Proteomics6.2 Market Sizing and Forecast6.2.1 By Application6.2.2 By End User7 Markets - Competitive Benchmarking & Company Profiles7.1 Global Proteomics Market: Competitive Landscape7.1.1 Corporate Strategies, January 2022-December 20247.1.2 Partnerships, Alliances, and Business Expansions7.1.3 Mergers and Acquisitions7.1.4 New Offerings7.2 Company Profiles7.2.1 Overview7.2.2 Top Products/Services7.2.3 Top Competitors7.2.4 Target Customers7.2.5 Key Personnel7.2.6 Analyst View Agilent Technologies, Inc. Applied Biomics Biognosys AG Bio-Rad Laboratories, Inc. Danaher Corporation DiaSorin S.p.A. Illumina, Inc. Merck KGaA MS Bioworks Promega Corporation Oxford Expression Technologies Ltd. Revvity, Inc. Standard BioTools Inc. Takara Bio Inc. Thermo Fisher Scientific Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Proteomics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
